Madrid, May 20, 2025
As part of our growth and consolidation plan, i+Med has officially inaugurated its new headquarters in Madrid, a strategic milestone that strengthens our national presence and brings us closer to a more accessible, personalized, and science-based medicine.
Located at the iconic Ortega y Gasset 58, in the heart of the Salamanca district, this new branch represents more than just an expansion of our facilities: it is a space for connection, communication, and collaboration between our team, healthcare professionals, and society. Madrid thus becomes a key point in our roadmap toward 2030.
As i+Med CEO Manu Muñoz states, “This opening marks a new milestone in our mission to get closer to both national and international clients, attract talent, and generate impact as a cooperative of scientists, from a city that is a strategic hub for health, innovation, and global influence.”
A multifunctional center designed to keep growing, share knowledge, and connect with the general public
This new space includes:
- A corporate office area, from which part of the company’s commercial operations will be coordinated nationally and internationally, with capacity to grow the team and strengthen our network of strategic alliances.
- A medical training center that will host scientific meetings, workshops, technical sessions, and demonstrations aimed at professionals in the pharmaceutical, biomedical, and clinical sectors. This space will be key in bringing innovation closer to those who apply our solutions in daily healthcare practice.
- A permanent store for Sibari Republic, our renowned high-end cosmetics brand, offering direct service to the public with access to products, experiences, and exclusive launches.
The inauguration, held on May 20, brought together more than one hundred professionals from the medical, academic, and institutional fields. It was a moment of deep significance for us, an opportunity to share our vision for the future and create new synergies to strengthen the ecosystem of scientific talent, biomedical innovation, and the pharmaceutical industry in our country.
